Druckenmiller's cholesterol bet gets swept up in a rival's failure

Druckenmiller's fund holds NewAmsterdam at 4% of its stock portfolio, betting its oral pill obicetrapib wins as a cholesterol treatment. It sank 12% after Novartis's rival injectable flopped on September 5, though that drug works differently. NewAmsterdam's own trial results land later this year.